Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

ADMA Biologics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

28 Feb 2015 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - ADMA BIOLOGICS INC (ADMA-O)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

05 Mar 2015 Thomson Reuters Stock Report 11 $25.00

ValuEngine Industry Report for Medical-biomed/genetics(ADMA)

Advanced academic research that brings you superior investment strategies in an actionable format. Industry Analysis Report, ...

05 Mar 2015 ValuEngine, Inc. 10 $49.00

Wright Investors Service Comprehensive Report for Adma Biologics Inc

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

04 Mar 2015 Wright Reports 52 $75.00

ValuEngine Rating and Forecast Report for ADMA

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

02 Mar 2015 ValuEngine, Inc. 11 $25.00

ADMA BIOLOGICS INC (ADMA) 12-months forecast

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

28 Feb 2015 Pechala's Reports 1 $15.00

ADMA BIOLOGICS INC (ADMA) - REPORT FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

28 Feb 2015 Pechala's Reports 1 $25.00

ADMA BIOLOGICS (ADMA) Zacks Company Snapshot

23 Feb 2015 Zacks Investment Research Inc. 1 $12.00

ADMA: Compelling RI-002 Phase III study 2nd endpoint results suggest RI-002 could be an important commercial product; Increase TP to $20

This morning, ADMA reported robust 2nd endpoint results from the RI-002 in primary immune deficiency disease (PIDD) Phase II...

23 Feb 2015 Laidlaw & Company 10 $25.00

TheStreet.com Ratings Stock Report For: ADMA BIOLOGICS INC (ADMA)

22 Feb 2015 TheStreet.com Ratings 5 $10.00